SLGL Sol-Gel Technologies Ltd.

+0.27  (+3%)
Previous Close 8.23
Open 8.22
Price To Book 2.94
Market Cap 161,074,728
Shares 18,949,968
Volume 13,382
Short Ratio
Av. Daily Volume 24,901

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2020 with data due 2021.
Phase 3 data due 4Q 2019.
Phase 3 top-line data met primary endpoints - July 8, 2019.
VERED (Epsolay)
Papulopustular rosacea
Proof of concept trial to commence 1Q 2020.
Palmoplantar keratoderma (PPK)

Latest News

  1. Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
  2. Sol-Gel Announces Pricing of Public Offering of Ordinary Shares
  3. Sol-Gel Technologies Ltd. (SLGL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  4. Sol-Gel Technologies Hosting Analyst & Investor Day
  5. Investors Who Bought Sol-Gel Technologies (NASDAQ:SLGL) Shares A Year Ago Are Now Up 49%
  6. Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream
  7. UPDATE: Sol-Gel Technologies shares soar 9.5% on news of positive results in trials of rosacea treatment
  8. Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea
  9. Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019
  10. Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo
  11. Sol-Gel to Present at Upcoming Healthcare Investor Conferences in June
  12. Sol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update
  13. Analysts Estimate Sol-Gel Technologies Ltd. (SLGL) to Report a Decline in Earnings: What to Look Out for
  14. Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
  15. Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris
  16. Supernus' ADHD Candidate Positive in 4th Phase III Study
  17. Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
  18. Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
  19. What Percentage Of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares Do Insiders Own?
  20. Sol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%